Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).

Metenova is a leading innovator and manufacturer of magnetic mixers for pharmaceutical and biotechnology applications. The company is headquartered in Mölndal, Gothenburg.

The acquisition of Metenova strengthens Repligen's fluid management portfolio, with a product line that expands on the success of Repligen's systems and fluid management assemblies.

Vinge's team mainly consisted of Jonas Bergström, Johanna Wiberg, Viktor Lennartsson, Robin Sultani (M&A), Sam Seddigh, Hanna Marberg (employment), David Olander (competition), Mathilda Persson, Mika Jordan, Arthur Kinski, Mario Saad (commercial agreements), Christoffer Nordin (Life Science/Regulatory), Lisa Hörnqvist (IT and GDPR), Stojan Arnerstål, Axel Lennartsson, Johan Gavelin (IP), Kristoffer Larson (real property), Mia Falk (compliance), Anders Leissner (sanctions/export control) and Cecilia Loctander (project assistant).


Vinge has advised Cell Impact in connection with its rights issue

Vinge has advised Cell Impact AB (publ) in connection with a partly guaranteed rights issue which will provide Cell Impact with issue proceeds of SEK 129 million before deduction of transaction costs
December 06, 2023

Vinge has advised Triton in connection with sale of shares in Ambea AB (publ)

In total, 8.4 million shares were placed at a price of SEK 43.50 per share, corresponding to a total value of approximately SEK 365 million.
November 29, 2023

Vinge represents Lassie AB in a capital raising of SEK 260 million

Vinge has advised the pet insurance broker Lassie AB in connection with a capital raising of SEK 260 million in order to continue the expansion of the business.
November 29, 2023